Patents Examined by Brian E McDowell
  • Patent number: 12221450
    Abstract: Compounds for treating a microbial and/or bacterial infection and, particularly, to compounds that are 5-(substituted phenyl)-7-thioxo-7,8-dihydropyrimido[4,5-d]pyrimidine-2,4(1H,3H)-dione analogues and their use as anti-microbial or anti-bacterial agents.
    Type: Grant
    Filed: March 27, 2024
    Date of Patent: February 11, 2025
    Assignee: KING FAISAL UNIVERSITY
    Inventors: Katharigatta N. Venugopala, Pran Kishore Deb, Vinuta Kamat, Rangappa Santosh, Boja Poojary, Manohar S. Kugaji, Vijay M. Kumbar, Mohamed A. Morsy, Bandar Aldhubiab, Mahesh Attimarad, Anroop B. Nair, Nagaraja Sreeharsha
  • Patent number: 12209098
    Abstract: The present invention relates to compounds of formula I: in which p, q, Y1, Y2, R1, R2a, R2b, R3a, R3b, R4a, R4b, R5a, R5b, R7 and R8 are defined in the Summary of the Invention; capable of inhibiting the activity of SHP2. The invention further provides a process for the preparation of compounds of the invention, pharmaceutical preparations comprising such compounds and methods of using such compounds and compositions in the management of diseases or disorders associated with the aberrant activity of SHP2.
    Type: Grant
    Filed: February 23, 2021
    Date of Patent: January 28, 2025
    Assignee: NOVARTIS AG
    Inventors: Christine Hiu-Tung Chen, Zhuoliang Chen, Michael Dore, Jorge Garcia Fortanet, John William Giraldes, Rajesh Karki, Mitsunori Kato, Matthew J. LaMarche, Lawrence Blas Perez, Martin Sendzik, Troy Douglas Smith, Bakary-Barry Toure, Sarah Williams
  • Patent number: 12195451
    Abstract: Provided are compounds of Formula III that enhance the efficacy of viruses by increasing spread of the virus in cells, increasing the titer of virus in cells, or increasing the antigen expression from a virus, gene or trans-gene expression from a virus, or virus protein expression in cells. Other uses, compositions and methods of using same are also provided.
    Type: Grant
    Filed: March 31, 2022
    Date of Patent: January 14, 2025
    Assignee: Ottawa Hospital Research Institute and University of Ottawa
    Inventors: Jean-Simon Diallo, Christopher Noyce Boddy, Mark Dornan, Ramya Krishnan, Rozanne Arulanandam, Fabrice Le Boeuf, Jeffrey Smith, Andrew Macklin
  • Patent number: 12186313
    Abstract: The present invention provides compounds of formula (I) and pharmaceutically acceptable salts thereof, wherein R1 and R2 are as defined in the specification, processes for their preparation, pharmaceutical compositions containing them and their use in therapy.
    Type: Grant
    Filed: August 30, 2021
    Date of Patent: January 7, 2025
    Assignee: Takeda Pharmaceutical Company Limited
    Inventors: William Farnaby, Charlotte Fieldhouse, Katherine Hazel, Catrina Kerr, Natasha Kinsella, David Livermore, Kevin Merchant, David Miller
  • Patent number: 12187707
    Abstract: A pharmaceutical formulation of N-(2-(2-(dimethylamino)ethoxy)-4-methoxy-5-((4-(1-methyl-1H-indol-3-yl)pyrimidin-2-yl)amino)phenyl)acrylamide (compound 1), in particular methanesulfonic acid salt thereof, and methods of using the pharmaceutical formulation for the treatment or prevention of diseases or medical conditions mediated through mutated forms of epidermal growth factor receptor (EGER), such as various cancers, are disclosed.
    Type: Grant
    Filed: November 12, 2021
    Date of Patent: January 7, 2025
    Assignee: BETA PHARMA, INC.
    Inventors: Michael Nicholas Greco, Michael John Costanzo, Michael Alan Green, Jirong Peng, Victoria Lynn Wilde, Don Zhang
  • Patent number: 12180173
    Abstract: A 5-((2-isopropyl-5-methylphenoxy)methyl)-3-(naphthalen-1-yl)-1,2,4-oxadiazole compound, having the formula I: can be used as an antimicrobial agent.
    Type: Grant
    Filed: April 1, 2024
    Date of Patent: December 31, 2024
    Assignee: KING FAISAL UNIVERSITY
    Inventors: Hany Mohamed Abd El-Lateef Ahmed, Mai Mostafa Khalaf Ali, Antar Ahmed Abdelhamid Ahmed, Amer A. Amer
  • Patent number: 12180191
    Abstract: A 2-[(1H-benzimidazol-2-yl)imino]-5,5-diphenylimidazolidin-4-one compound, its synthesis, and its use as an antimicrobial agent.
    Type: Grant
    Filed: February 1, 2024
    Date of Patent: December 31, 2024
    Assignee: KING FAISAL UNIVERSITY
    Inventors: Mai Mostafa Khalaf Ali, Hany Mohamed Abd El-Lateef Ahmed, Amer A Amer, Antar Ahmed Abdelhamid Ahmed
  • Patent number: 12180227
    Abstract: The present invention relates to novel diazabicyclically substituted imidazo[1,2-a]pyrimidine derivatives, such as compounds of the general formula (I): to methods for producing the same, to the use thereof either alone or in combinations for the treatment and/or prevention of diseases, as well as to their use for preparing medicaments for the treatment and/or prevention of diseases, especially for treatment and/or prevention of breathing disorders, including sleep-related breathing disorders such as obstructive and central sleep apnoea and snoring.
    Type: Grant
    Filed: July 16, 2021
    Date of Patent: December 31, 2024
    Assignees: Bayer Aktiengesellschaft, Bayer Pharma Aktiengesellschaft
    Inventors: Martina Delbeck, Michael Hahn, Thomas Müller, Klemens Lustig, Karl Collins, Niels Lindner, Janine Nicolai, Moritz Beck-Broichsitter, Udo Albus, Doris Gehring, Björn Rosenstein
  • Patent number: 12162818
    Abstract: The present disclosure provides compounds of Formula (VIIb) and methods for inhibiting or degrading the N-terminal domain of the androgen receptor, as well as methods for treating cancers such as prostate cancer.
    Type: Grant
    Filed: January 13, 2022
    Date of Patent: December 10, 2024
    Assignees: The Regents of the University of California, The United States Government represented by the Department of Veterans Affairs
    Inventors: Matthew Rettig, Michael E. Jung, D. Elshan Nakath G. Ralalage, Jiabin An
  • Patent number: 12157740
    Abstract: Pharmaceutical compounds, compositions, methods, and uses therefor are presented using selected triazolopyridines and triazolopyrimidines to inhibit or reduce phosphorylation of tau proteins or that act as antagonists of corticotropin-releasing factor. Viewed from another perspective, compounds, compositions, and methods are presented for treating or preventing symptoms of Alzheimer's disease by inhibiting or reducing the phosphorylation of tau proteins.
    Type: Grant
    Filed: September 2, 2021
    Date of Patent: December 3, 2024
    Assignee: NantNeuro, LLC
    Inventors: Varghese John, Dale Bredesen, Patricia Spilman, Barbara Jagodzinska
  • Patent number: 12157729
    Abstract: The present disclosure encompasses solid state forms of Belumosudil, in embodiments crystalline polymorphs of Belumosudil or salts thereof, processes for preparation thereof, and pharmaceutical compositions thereof.
    Type: Grant
    Filed: December 22, 2023
    Date of Patent: December 3, 2024
    Assignee: TEVA PHARMACEUTICALS INTERNATIONAL GMBH
    Inventors: Polina Lapido, Inbal Shumacher, Ofir Shaul
  • Patent number: 12157745
    Abstract: A compound represented by following formula I: according to the present disclosure. The disclosed compound is useful in the treatment of many disease states related to cell proliferation. In particular, new pyran derivatives are provided along with processes for preparations and methods for pharmaceutical applications, for example, as anticancer agents. The compound was found to have antiproliferative effects against multiple cancer cell lines and showed low toxicity to normal fibroblasts. The disclosed compound also exhibited anticancer properties by inducing caspase-mediated cell death mechanisms and arresting cancer cell progression. Further, the compound represented by Formula I targets multiple key proteins/enzymes, including thioredoxin reductase, glutathione reductase, transferrin receptors, inisitol-3-phosphate synthase, cystolic aminopeptidase, and transketolase, which are over-expressed in tumor cells.
    Type: Grant
    Filed: December 4, 2020
    Date of Patent: December 3, 2024
    Assignee: UNIVERSITY OF SHARJAH
    Inventors: Taleb H. Altel, Raafat A El-Awady, Srinivasulu Vunnam, Cijo George Vazhappilly, Hany A. Omar
  • Patent number: 12152009
    Abstract: A main object of the present invention is to provide a novel crystal of 2-{4-[N-{5, 6-diphenylpyrazin-2-yl}-N-isopropylamino]butyloxy}acetic acid (hereinafter referred to as “Compound B”). A form-I crystal of Compound B, which shows peaks at diffraction angles (2?) of 6.4°, 8.1°, 9.5°, 10.9°, 13.2°, 15.7°, 17.0°, 19.5°, 20.3°, 21.0°, and 22.8° in a powder X-ray diffraction spectrum obtained using a Cu-K? radiation (?=1.54 ?). A form-II crystal of Compound B, which shows peaks at diffraction angles (2?) of 9.6°, 11.4°, 11.7°, 16.3°, 17.5°, 18.5°, 18.7°, 19.9°, 20.1°, 21.0°, and 24.6° in a powder X-ray diffraction spectrum obtained using a Cu-K? radiation (?=1.54 ?).
    Type: Grant
    Filed: April 12, 2023
    Date of Patent: November 26, 2024
    Assignee: NIPPON SHINYAKU CO., LTD.
    Inventor: Toshio Fujiwara
  • Patent number: 12152018
    Abstract: This disclosure features chemical entities (e.g., a compound or a pharmaceutically acceptable salt, and/or hydrate, and/or cocrystal, and/or drug combination of the compound) having formula (I) that inhibit (e.g., antagonize) Stimulator of Interferon Genes (STING). Said chemical entities are useful, e.g., for treating a condition, disease or disorder in which increased (e.g., excessive) STING activation (e.g., STING signaling) contributes to the pathology and/or symptoms and/or progression of the condition, disease or disorder (e.g., cancer) in a subject (e.g., a human). This disclosure also features compositions containing the same as well as methods of using and making the same.
    Type: Grant
    Filed: January 7, 2022
    Date of Patent: November 26, 2024
    Assignee: IFM Due, Inc.
    Inventors: Shankar Venkatraman, Jason Katz, William R. Roush, Hans Martin Seidel
  • Patent number: 12145924
    Abstract: The present invention provides a compound of formula or a pharmaceutical salt thereof, use, methods for its preparation are described.
    Type: Grant
    Filed: May 18, 2022
    Date of Patent: November 19, 2024
    Assignee: ELI LILLY AND COMPANY
    Inventors: Tianwei Ma, Liang Wu, Xuejun Zhang
  • Patent number: 12139494
    Abstract: This invention provides an unexpectedly stable, highly crystalline form of the di-HCl salt of for advantageous therapeutic pharmaceutical efficacy and dosage form stability.
    Type: Grant
    Filed: February 28, 2022
    Date of Patent: November 12, 2024
    Inventors: Alexander Smith, Hannah S. White, Patricia Andres, Xufeng Sun, Lei Zhu, Petinka I. Vlahova
  • Patent number: 12144247
    Abstract: The present application relates to an organic compound, and an electronic device and electronic apparatus thereof. The organic compound of the present application has a structural formula shown in formula 1. When used in an electronic device, the organic compound of the present application can significantly improve the performance of the electronic device.
    Type: Grant
    Filed: March 17, 2022
    Date of Patent: November 12, 2024
    Assignee: SHAANXI LIGHTE OPTOELECTRONICS MATERIAL CO., LTD.
    Inventors: Ziwei Lin, Yingwen Li, Xinxuan Li, Youngkook Kim
  • Patent number: 12134607
    Abstract: Provided are type I, III, V and VI crystals of 1-((1R,2R)-2-hydroxy-4,4-dimethyl-1,2,3,4-tetrahydronaphthalen-1-yl)-3-(5-methyl-6-(2-methylpyrimidin-5-yl)-2-phenylpyridin-3-yl)urea which are useful as bulk pharmaceutical crystals. Also provided are type I, III, V and VI crystals of 1-((1R,2R)-2-hydroxy-4,4-dimethyl-1,2,3,4-tetrahydronaphthalen-1-yl)-3-(5-methyl-6-(2-methylpyrimidin-5-yl)-2-phenylpyridin-3-yl)urea having excellent TrkA inhibitory effect, medicines and medicinal composition containing these crystals, and a method for producing these crystals.
    Type: Grant
    Filed: April 1, 2022
    Date of Patent: November 5, 2024
    Assignee: MOCHIDA PHARMACEUTICAL CO., LTD.
    Inventors: Yuji Kawada, Fumihiko Saitoh, Hiroshi Nagasue, Tsutomu Satoh
  • Patent number: 12129256
    Abstract: A compound having the structure: or a pharmaceutically acceptable salt thereof, or a pharmaceutically acceptable solvate of said compound or pharmaceutically acceptable salt, wherein A, A? and A? are independently O, C?O, C—R? or N—R?, where R? and R? may independently be H, amino, —NR7COR6, COR6, —CONR7R8, C1-C6 alkyl, or hydroxy(C1-C6 alkyl), and R? may be present or absent, and is present where the rules of valency permit, and where not more than one of A, A? and A? is O or C?O; R0 and R are independently H, Br, Cl, F, or C1-C6 alkyl; R1 is H, C1-C6 alkyl, or hydroxy(C1-C6 alkyl); R2 is selected from the group consisting of H, C1-C6 alkyl, C1-C6 alkoxy, hydroxy(C1-C6 alkyl), phenyl(C1-C6 alkyl), formyl, heteroaryl, heterocyclic, —COR6, —OCOR6, —COOR6, —NR7COR6, —CONR7R8, and —(CH2)n—W, where W is cyano, hydroxy, C3-C8 cycloalkyl, —SO2NR7R8, and —SO2—R9, where R9 is C1-C6 alkyl, C3-C8 cycloalkyl, heteroaryl, or heterocyclic; wherein each of said alkyl, cycloalkyl, heterocyclic, or heteroaryl may be unsu
    Type: Grant
    Filed: September 7, 2022
    Date of Patent: October 29, 2024
    Assignee: PFIZER INC.
    Inventors: Matthew Frank Brown, Alpay Dermenci, Andrew Fensome, Brian Stephen Gerstenberger, Matthew Merrill Hayward, Dafydd Rhys Owen, Stephen Wayne Wright, Li Huang Xing, Xiaojing Yang
  • Patent number: 12122799
    Abstract: The present disclosure provides method of treating or preventing a microbial infection caused by a prokaryotic pathogen in a subject, the method comprising administering a compound of Formula (I) as set forth in the specification. In one embodiment, the prokaryotic pathogen belongs to the genus Staphylococcus.
    Type: Grant
    Filed: June 18, 2019
    Date of Patent: October 22, 2024
    Assignees: THE GEORGE WASHINGTON UNIVERSITY, A CONGRESSIONALLY CHARTERED NOT-FOR-PROFIT CORPORATION, WASHINGTON UNIVERSITY
    Inventors: Cynthia Dowd, Audrey Odom John, Rachel Edwards, Kenneth M. Heidel, Xu Wang, Rene Chofor